0001171843-22-007233.txt : 20221108 0001171843-22-007233.hdr.sgml : 20221108 20221108161041 ACCESSION NUMBER: 0001171843-22-007233 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221108 DATE AS OF CHANGE: 20221108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Anika Therapeutics, Inc. CENTRAL INDEX KEY: 0000898437 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 043145961 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14027 FILM NUMBER: 221368978 BUSINESS ADDRESS: STREET 1: 32 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: (781) 457-9000 MAIL ADDRESS: STREET 1: 32 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 FORMER COMPANY: FORMER CONFORMED NAME: ANIKA THERAPEUTICS INC DATE OF NAME CHANGE: 19970114 FORMER COMPANY: FORMER CONFORMED NAME: ANIKA RESEARCH INC DATE OF NAME CHANGE: 19930309 8-K 1 f8k_110822.htm FORM 8-K Form 8-K
0000898437 False 0000898437 2022-11-08 2022-11-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  November 8, 2022

_______________________________

Anika Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware001-1402704-3145961
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

32 Wiggins Avenue

Bedford, Massachusetts 01730

(Address of Principal Executive Offices) (Zip Code)

(781) 457-9000

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareANIKNASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
Item 2.02. Results of Operations and Financial Condition.

The following information, including the exhibit attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

On November 8, 2022, Anika Therapeutics, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2022. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number     Description
   
99.1 Press Release of Anika Therapeutics, Inc. dated November 8, 2022
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Anika Therapeutics, Inc.
   
  
Date: November 8, 2022By: /s/ CHERYL R. BLANCHARD        
  CHERYL R. BLANCHARD
  President and Chief Executive Officer
  

 

 EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

Anika Reports Third Quarter Fiscal 2022 Financial Results

Third Quarter Revenue Growth of 2%

Third Phase III Clinical Trial for Cingal®, Next Generation Osteoarthritis Pain Product, Achieved Primary Endpoint Demonstrating Superiority Over Steroid Alone

Pivotal Phase III Clinical Trial for Hyalofast®, HA-Based, Single-Stage Cartilage Repair Product, Reaches 96% Enrollment

Positive Feedback from Limited Market Release of New X-Twist™ Fixation System for Soft Tissue Repair; On Track for Full Market Release in Early 2023

On Track to Achieve Stated FY2022 Guidance

BEDFORD, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its third quarter ended September 30, 2022.

Third Quarter 2022 Financial Summary

  • Revenue in the third quarter of 2022 was $40.3 million, up 2% compared with $39.5 million in the third quarter of 2021.
    • OA Pain Management1 revenue of $25.7 million, down 2%
    • Joint Preservation and Restoration revenue of $11.8 million, up 6%
    • Non-Orthopedic1 revenue of $2.8 million, up 27%
  • Gross margin was 57%, including $1.6 million of non-cash acquisition-related expenses and $2.6 million product rationalization charges; Adjusted gross margin2 was 67%.
  • Net loss was ($4.2) million, or ($0.29) per share, compared to net income of $0.6 million, or $0.04 per diluted share, in the prior year. Adjusted net loss2 was ($0.7) million, or ($0.05) per share, compared to adjusted net income2 of $0.8 million, or $0.05 per diluted share, in the prior year.
  • Adjusted EBITDA2 was $4.1 million, compared to adjusted EBITDA2 of $5.7 million in the prior year.
  • Operating cash flow was $2.7 million; quarter ending cash was $87.8 million after a $4.3 million payment for acquisition-related contingent consideration, with no outstanding debt.

1 OA Pain Management was previously referred to as Joint Pain Management; Non-Orthopedic was previously referred to as Other.
2 See description of non-GAAP financial information contained in this release.

“We’re pleased with our third quarter accomplishments including our limited launch of the X-Twist Fixation System, successful results from our Cingal Phase III clinical trial, significant progress enrolling the Hyalofast pivotal clinical trial, and solid financial performance,” Cheryl R. Blanchard, Ph.D., Anika’s President and CEO, commented. “Our limited launch of the X-Twist platform has been very positive to date, and we remain on track for the full launch in early 2023. We also recently announced the successful results from our third Phase III clinical trial for Cingal which demonstrated superiority over steroid alone and we look forward to meeting with the FDA to determine next steps for U.S. regulatory approval. Despite the global macroeconomic environment, including staffing and supply chain challenges, we are confident that our strong cash position and no debt, robust foundation of clinical data, comprehensive product and technology portfolio, and exciting new product pipeline all position us for accelerated growth as we drive value for Anika shareholders.”

Recent 2022 Business Highlights

  • Continued Leadership in OA Pain Market
    • Maintained #1 U.S. market share position in OA Pain Management with Monovisc® and Orthovisc®. In August 2022, DePuy Mitek extended our license and supply agreement for Orthovisc for another 5-year term through December 2028.
    • International viscosupplement sales continued accelerated growth, including Cingal which is currently sold in over 35 countries.
  • Building a Best-in-Class Portfolio of Joint Preservation and Restoration Solutions
    • Continued accelerated growth of Tactoset®, Anika’s regenerative solution for insufficiency fractures and soft tissue hardware augmentation, with multiple planned 510(k) filings targeting further expansion.
    • First surgeries were performed with strong positive surgeon feedback during the limited market release of the X-Twist Fixation System, a new addition to the Anika sports medicine portfolio that addresses the needs of surgeons performing high volume soft tissue repair procedures, such as rotator cuff; on track for a full market release in early 2023.
    • Advanced development of multiple new products across the largest and fastest growing parts of the joint preservation market, including new innovative shoulder implants and a regenerative rotator cuff repair system.
  • Ramping Up Medical Education Activities
    • Held multiple medical education events, training more than 400 U.S. surgeons in-person to date this year in addition to other training activities at industry meetings.
  • Advancing Cingal Towards U.S. Regulatory Approval
    • Announced that Cingal, Anika’s next generation product for osteoarthritis patients, successfully achieved its primary endpoint in a third Phase III clinical trial, Cingal 19-01, which demonstrated the superiority of Cingal over steroid alone, for OA pain relief at 26 weeks.
    • Together with previous studies, Cingal has now demonstrated superiority over each of its active ingredients and placebo, and consistently demonstrating strong and durable pain relief in OA patients.
    • Company to engage with the FDA in the coming months regarding next steps for U.S. regulatory approval and explore the potential to advance Cingal through commercial partnerships in the U.S. and select Asian markets. These efforts will inform next steps, including if and how to proceed with another clinical trial in the United States.
  • Continuing Clinical Trial Enrollment for Hyalofast Pivotal Phase III Clinical Trial
    • Delivered significant progress towards clinical study enrollment for the Company’s differentiated HA-based single-stage cartilage repair product, Hyalofast, which is now 96% enrolled with 193 patients randomized between Hyalofast implantation and the microfracture surgical technique.
    • Company expects the trial to be fully enrolled in early 2023 and remains on track to file a Pre-Market Approval with the FDA in 2025.

Fiscal 2022 Outlook
The Company continues to expect its overall revenue for fiscal year 2022 to be toward the upper end of its guidance range of low to mid single-digit growth compared with 2021. Revenue ranges by product family are:

  • OA Pain Management up mid to upper single-digit percent (previously low single-digit percent)
  • Joint Preservation and Restoration up low to mid single-digit percent (previously mid single to low double-digit percent)
  • Non-Orthopedic down approximately 20% due largely to legacy product rationalization  

There remains volatility and uncertainty in the global macroeconomic environment and the Company’s outlook for fiscal 2022 is subject to the changing dynamics associated with staffing shortages, supply chain disruption, inflation and other direct and indirect impacts of the COVID pandemic.

Conference Call Information
Anika’s management will hold a conference call and webcast to discuss its financial results and business highlights today, Tuesday, November 8, 2022, at 5:00 pm ET. The conference call can be accessed by dialing 1-888-256-1007 (toll-free domestic) or 1-856-344-9221 (international) and providing the conference ID number 2205523. A live audio webcast will be available in the Investor Relations section of Anika’s website, www.anika.com. A slide presentation with highlights from the conference call will be available in the Investor Relations section of the Anika website. A replay of the webcast will be available on Anika’s website approximately two hours after the completion of the event.

About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, sports medicine soft tissue repair and bone preserving joint technologies, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.

ANIKA, ANIKA THERAPEUTICS, CINGAL, HYALOFAST, MONOVISC, ORTHOVISC, TACTOSET, X-TWIST and the Anika logo are registered trademarks of Anika Therapeutics, Inc. or its subsidiaries.

Non-GAAP Financial Information
Non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with GAAP. Furthermore, the Company’s definition of non-GAAP measures may differ from similarly titled measures used by others. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, Anika strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. The Company presents these non-GAAP financial measures because it uses them as supplemental measures in internally assessing the Company’s operating performance, and, in the case of Adjusted EBITDA, it is set as a key performance metric to determine executive compensation. The Company also recognizes that these non-GAAP measures are commonly used in determining business performance more broadly and believes that they are helpful to investors, securities analysts, and other interested parties as a measure of comparative operating performance from period to period.

Adjusted Gross Margin
Adjusted gross margin is defined by the Company as adjusted gross profit divided by total revenue. The Company defines adjusted gross profit as GAAP gross profit excluding amortization of certain acquired assets, the impact of inventory fair-value step up associated with our recent acquisitions and non-cash product rationalization charges.

Adjusted EBITDA
Adjusted EBITDA is defined by the Company as GAAP net income (loss) excluding depreciation and amortization, interest and other income (expense), income taxes, stock-based compensation expense, acquisition related expenses, non-cash charges related to goodwill impairment and changes in the fair value of contingent consideration associated with the Company’s recent acquisitions as a result of the COVID pandemic, and non-cash product rationalization charges.

Adjusted Net Income (Loss) and Adjusted EPS
Adjusted net income (loss) is defined by the Company as GAAP net income excluding acquisition related expenses, inclusive of the impact of purchase accounting, on a tax effected basis, and the non-cash product rationalization charges. In the context of adjusted net income (loss), the impact of purchase accounting includes amortization of inventory step up and intangible assets recorded as part of purchase accounting for acquisition transactions. The amortized assets contribute to revenue generation, and the amortization of such assets will recur in future periods until such assets are fully amortized. These assets include the estimated fair value of certain identified assets acquired in acquisitions in 2020 and beyond, including in-process research and development, developed technology, customer relationships and acquired tradenames. As a result of COVID, the Company is also specifically excluding the impacts of goodwill impairment charges and changes in the fair value of contingent consideration associated with the acquisition transactions, each on a tax effected basis. Adjusted diluted EPS is defined by the Company as GAAP diluted EPS excluding acquisition related expenses and the impact of purchase accounting, each on a tax-adjusted per share basis, and non-cash product rationalization charges. Again, the Company is also specifically excluding the impacts of goodwill impairment charges and changes in the fair value of contingent consideration associated with recent acquisition transactions, each on a tax effected basis if applicable.

A reconciliation of adjusted gross profit to gross profit (and the associated adjusted gross margin calculation), adjusted EBITDA to net income (loss), adjusted net income (loss) to net income (loss) and adjusted diluted EPS to diluted EPS, the most directly comparable financial measures calculated and presented in accordance with GAAP, is shown in the tables at the end of this release.

Forward-Looking Statements
This press release may contain forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning the Company's expectations, anticipations, intentions, beliefs or strategies regarding the future which are not statements of historical fact, including the subheadings at the top of the press release with respect to the planned launch of the X-Twist and FY2022 guidance, the second, third and final sentences of Dr. Blanchard’s quote, the bullets with respect to the planned launch of the X-Twist, the anticipated meeting with the FDA and potential partnerships regarding Cingal, and the anticipated Hyalofast enrollment and filing of a Pre-Market Approval, all in the section titled Recent 2022 Business Highlights, and the statements made in the section titled Fiscal 2022 Outlook. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks, uncertainties, and other factors. The Company's actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including, but not limited to, (i) the Company's ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all; (ii) the Company's ability to obtain pre-clinical or clinical data to support domestic and international pre-market approval applications, 510(k) applications, or new drug applications, or to timely file and receive FDA or other regulatory approvals or clearances of its products; (iii) that such approvals will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (iv) the Company's research and product development efforts and their relative success, including whether we have any meaningful sales of any new products resulting from such efforts; (v) the cost effectiveness and efficiency of the Company's clinical studies, manufacturing operations, and production planning; (vi) the strength of the economies in which the Company operates or will be operating, as well as the political stability of any of those geographic areas; (vii) future determinations by the Company to allocate resources to products and in directions not presently contemplated; (viii) the Company's ability to successfully commercialize its products, in the U.S. and abroad; (ix) the Company's ability to provide an adequate and timely supply of its products to its customers; and (x) the Company's ability to achieve its growth targets. Additional factors and risks are described in the Company's periodic reports filed with the Securities and Exchange Commission, and they are available on the SEC's website at www.sec.gov. Forward-looking statements are made based on information available to the Company on the date of this press release, and the Company assumes no obligation to update the information contained in this press release.

For Investor Inquiries:
Anika Therapeutics, Inc.
Mark Namaroff, 781-457-9287
Vice President, Investor Relations, ESG and Corporate Communications
investorrelations@anika.com

Anika Therapeutics, Inc. and Subsidiaries
Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)
         
  For the Three Months Ended September 30, For the Nine Months Ended September 30,
   2022   2021   2022   2021 
Revenue $40,264  $39,536  $116,614  $111,973 
Cost of Revenue  17,485   16,513   47,169   47,164 
Gross Profit  22,779   23,023   69,445   64,809 
         
Operating expenses:        
Research and development  7,301   7,673   20,433   21,327 
Selling, general and administrative  21,276   17,500   61,745   53,664 
Change in fair value of contingent consideration  -   (3,450)  -   (21,920)
Total operating expenses  28,577   21,723   82,178   53,071 
(Loss) income from operations  (5,798)  1,300   (12,733)  11,738 
Interest and other income (expense), net  436   (48)  378   (141)
(Loss) income before income taxes  (5,362)  1,252   (12,355)  11,597 
(Benefit from) provision for income taxes  (1,187)  694   (2,404)  1,670 
Net (loss) income $(4,175) $558  $(9,951) $9,927 
         
Net (loss) income per share:        
  Basic $(0.29) $0.04  $(0.68) $0.69 
  Diluted $(0.29) $0.04  $(0.68) $0.68 
         
Weighted average common shares outstanding:        
  Basic  14,603   14,429   14,542   14,389 
  Diluted  14,603   14,647   14,542   14,588 
         


Anika Therapeutics, Inc. and Subsidiaries
Consolidated Balance Sheets
(in thousands, except per share data)
 (unaudited)
    
 September 30, December 31,
ASSETS 2022   2021 
Current assets:   
Cash, cash equivalents and investments$87,777  $94,386 
Accounts receivable, net 34,168   29,843 
Inventories, net 37,237   36,010 
Prepaid expenses and other current assets 8,579   8,289 
Total current assets 167,761   168,528 
Property and equipment, net 47,390   47,602 
Right-of-use assets 30,987   20,957 
Other long-term assets 18,342   20,285 
Intangible assets, net 76,545   82,382 
Goodwill 6,721   7,781 
Total assets$347,746  $347,535 
    
LIABILITIES AND STOCKHOLDERS' EQUITY   
Current liabilities:   
Accounts payable$8,353  $7,633 
Accrued expenses and other current liabilities 17,999   17,847 
Contingent consideration -   4,315 
Total current liabilities 26,352   29,795 
Other long-term liabilities 474   1,258 
Deferred tax liability 6,800   10,157 
Lease liabilities 29,183   19,240 
    
Stockholders' equity:   
Common stock, $0.01 par value 146   144 
Additional paid-in-capital 76,661   67,081 
Accumulated other comprehensive loss (7,497)  (5,718)
Retained earnings 215,627   225,578 
Total stockholders' equity 284,937   287,085 
Total liabilities and stockholders' equity$347,746  $347,535 


Anika Therapeutics, Inc. and Subsidiaries
Reconciliation of GAAP Gross Profit to Adjusted Gross Profit
(in thousands)
(unaudited)
         
  For the Three Months Ended September 30, For the Nine Months Ended September 30,
   2022   2021   2022   2021 
Gross Profit $22,779  $23,023  $69,445  $64,809 
Product rationalization related charges  2,636     2,636   2,063 
Acquisition related intangible asset amortization  1,562   1,562   4,686   4,686 
Acquisition related inventory step up  -   1,458   -   6,244 
Adjusted Gross Profit $26,977  $26,043  $76,767  $77,802 
         
Unadjusted Gross Margin  57%  58%  60%  58%
Adjusted Gross Margin  67%  66%  66%  69%
         
         
Anika Therapeutics, Inc. and Subsidiaries
Reconciliation of GAAP Net Income to Adjusted EBITDA
(in thousands)
(unaudited)
         
  For the Three Months Ended September 30, For the Nine Months Ended September 30,
   2022   2021   2022   2021 
Net (loss) income $(4,175) $558  $(9,951) $9,927 
Interest and other expense, net  (436)  48   (378)  141 
Benefit from income taxes  (1,187)  694   (2,404)  1,670 
Depreciation and amortization  1,549   1,789   4,980   5,226 
Stock-based compensation  3,876   2,863   10,502   7,919 
Product rationalization  2,636   -   2,636   2,063 
Acquisition related intangible asset amortization  1,787   1,787   5,361   5,361 
Acquisition related inventory step up  -   1,458   -   6,244 
Change in fair value of contingent consideration  -   (3,450)  -   (21,920)
Adjusted EBITDA $4,050  $5,747  $10,746  $16,631 
         
         
Anika Therapeutics, Inc. and Subsidiaries
Reconciliation of GAAP Net Income to Adjusted Net Income
(in thousands)
(unaudited)
         
  For the Three Months Ended September 30, For the Nine Months Ended September 30,
   2022   2021   2022   2021 
Net (loss) income $(4,175) $558  $(9,951) $9,927 
Product rationalization, tax effected  2,056   -   1,947   1,590 
Acquisition related intangible asset amortization, tax effected  1,394   1,146   3,960   3,898 
Acquisition related inventory step up, tax effected  -   935   -   4,626 
Change in fair value of contingent consideration, tax effected  -   (1,865)  -   (17,152)
Adjusted net (loss) income $(725) $774  $(4,044) $2,889 
         
         
Anika Therapeutics, Inc. and Subsidiaries
Reconciliation of GAAP Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share
(per share data)
(unaudited)
         
  For the Three Months Ended September 30, For the Nine Months Ended September 30,
   2022   2021   2022   2021 
Diluted (loss) earnings per share (EPS) $(0.29) $0.04  $(0.68) $0.68 
Product rationalization, tax effected  0.14   -   0.13   0.11 
Acquisition related intangible asset amortization, tax effected  0.10   0.08   0.27   0.27 
Acquisition related inventory step up, tax effected  -   0.06   -   0.32 
Change in fair value of contingent consideration, tax effected  -   (0.13)  -   (1.18)
Adjusted diluted (loss) earnings per share (EPS) $(0.05) $0.05  $(0.28) $0.20 
         


Anika Therapeutics, Inc. and Subsidiaries
Revenue by Product Family
(in thousands, except percentages)
(unaudited)
                
 For the Three Months Ended September 30, For the Nine Months Ended September 30,
  2022   2021  $ change % change  2022   2021  $ change % change
OA Pain Management$25,665  $26,153  $(488) -2% $74,139  $69,790  $4,349  6%
Joint Preservation and Restoration 11,821   11,193   628  6%  36,055   35,296   759  2%
Non-Orthopedic 2,778   2,190   588  27%  6,420   6,887   (467) -7%
Revenue$40,264  $39,536  $728  2% $116,614  $111,973  $4,641  4%

 

 EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Nov. 08, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 08, 2022
Entity File Number 001-14027
Entity Registrant Name Anika Therapeutics, Inc.
Entity Central Index Key 0000898437
Entity Tax Identification Number 04-3145961
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 32 Wiggins Avenue
Entity Address, City or Town Bedford
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01730
City Area Code 781
Local Phone Number 457-9000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol ANIK
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 f8k_110822_htm.xml IDEA: XBRL DOCUMENT 0000898437 2022-11-08 2022-11-08 iso4217:USD shares iso4217:USD shares 0000898437 false 8-K 2022-11-08 Anika Therapeutics, Inc. DE 001-14027 04-3145961 32 Wiggins Avenue Bedford MA 01730 781 457-9000 false false false false Common Stock, par value $0.01 per share ANIK NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_110822.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_110822.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "inline": { "local": [ "f8k_110822.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_110822.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_110822.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001171843-22-007233-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-22-007233-xbrl.zip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end